# Minghui Pharmaceutical and ASKA Pharmaceutical Enter into Exclusive License Agreement for the IGF-1R Antibody in Japan

- Source: PR Newswire M&A
- Published: 2026-11-04T06:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/minghui-pharmaceutical-and-aska-pharmaceutical-enter-into-exclusive-license-agreement-for-the-igf-1r-antibody-in-japan-302928762.html
- Canonical: https://groundlevelnews.com/story/minghui-pharmaceutical-and-aska-pharmaceutical-enter-into-exclusive-li-7b8b13/

HANGZHOU, China, SHANGHAI and TOKYO, Nov. 4, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan. MHB018A...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._